Dynavax Technologies Corp DVAX is trading lower after the company announced Valneva SE VALN received a termination notice from the United Kingdom government in relation to Valneva's supply agreement for its COVID-19 vaccine candidate, VLA2001.
Valneva said it intends to continue clinical development of VLA2001, which is currently in Phase 3 trials. Phase 3 results are expected to be available early in the fourth quarter.
"Valneva is one of a number of companies developing COVID vaccines using CpG 1018 as an adjuvant and we continue to look forward to the upcoming Phase 3 clinical trial results for Valneva's inactivated COVID-19 vaccine adjuvanted with CpG 1018," said Ryan Spencer, CEO of Dynavax.
"The first COVID-19 vaccine that uses CpG 1018 was recently authorized by regulatory authorities and we look forward to the potential authorization of additional Dynavax-enabled COVID-19 vaccines in the months and quarters ahead," Spencer added.
Dynavax is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation.
DVAX Price Action: Dynavax has traded as high as $20.40 and as low as $3.58 over a 52-week period.
The stock was down 11.2-% at $15.58 at time of publication.
Photo: Torstensimon from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
